Skip to main content

Table 1 Baseline and demographic characteristics

From: A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

Characteristic

LY2140023

SOC

pValue*

(N = 130)

(N = 131)

Age, years, mean (SD)

38.7 (10.9)

39.5 (12.5)

.579

Gender – female, n (%)

45 (34.6)

44 (33.6)

.897

Race, n (%)

-

-

.669

  American Indian or Alaska Native

20 (15.4)

18 (13.7)

-

  Black/African American

44 (33.8)

39 (29.8)

-

  Multiple

1 (0.8)

3 (2.3)

 

  White

65 (50.0)

71 (54.2)

-

Diagnosis, n (%)

-

-

.202

  Catatonic

1 (0.8)

0 (0.0)

-

  Disorganized

8 (6.2)

4 (3.1)

-

  Paranoid

100 (76.9)

109 (83.2)

-

  Residual

7 (5.4)

2 (1.5)

 

  Undifferentiated

14 (10.8)

16 (12.2)

-

Weight, kg, mean (SD)

83.0 (21.5)

82.7 (21.7)

.907

Age of first episode, years, mean (SD)

24.6 (8.3)

23.1 (8.5)

.148

Episodes in the last 24 months, mean (SD)

1.8 (1.6)

2.0 (2.1)

.297

CGI-S, mean (SD)

3.8 (0.7)

3.7 (0.6)

.943

PANSS total, mean (SD)

85.6 (14.8)

85.1 (15.8)

.788

PANSS positive, mean (SD)

17.6 (4.7)

18.1 (4.8)

.355

PANSS negative, mean (SD)

26.2 (4.9)

25.7 (5.2)

.403

PANSS general psychopathology, mean (SD)

41.9 (9.1)

41.4 (9.3)

.644

Negative Assessment Scale-16, mean (SD)

58.7 (11.0)

57.3 (11.3)

.336

  1. Abbreviations: CGI-S Clinical global impressions Severity, n/N Number of patients, PANSS Positive and negative syndrome scale, SD Standard deviation.
  2. Groups: LY2140023, LY2140023 monohydrate, SOC, Standard-of-care.
  3. * P < .05, LY2140023 versus SOC.